Pulmonary embolism (PE) is the third most common cardiovascular disease after myocardial
infarction and stroke, and one of the leading causes of death in Europe. Aim. Analysis of the …

Background: Depending on the severity of clinical condition, acute pulmonary embolism
(APE) is treated with unfractionated heparin (UFH), low-molecular weight heparin (LMWH) …

Pulmonary thromboembolism is a very common cardiovascular disease, with a high
mortality rate. Despite the clear guidelines, this disease still represents a great challenge …

Aim. To perform the analysis of antithrombotic therapy and immediate prognosis in patients
with pulmonary embolism (PE) in routine clinical practice. Materials and methods. During 13 …

The prevalence and mortality due to venous thromboembolism (VTE) occupies a leading
position among the population throughout the world. The incidence and severity of VTE …

Venous thromboembolism (VTE) is one of the most common cardiovascular disease, and
can lead to death or the development of complications and disability. Modern approaches to …

Historically, standard treatment of haemodynamically stable pulmonary embolism (PE) in the
acute phase consists in parenteral anticoagulants overlapped with oral anticoagulants …

The clinical management of patients with acute pulmonary embolism is rapidly changing
over the years. The widening spectrum of clinical management strategies for these patients …

The introduction of factor Xa inhibitors advocated the initiation of clinical trials that
addressed the value of anticoagulation in patients with hemodynamically stable primary …

The overall objective of the Polish guidelines for the prevention and treatment of venous
thromboembolism is to increase patient benefit and safety by appropriate prevention and …